Healthcare provider profile · identity verified

Danny D Anchondo, MD

Internal Medicine · EL PASO, TX · NPI 1255969622

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	224	110
Amlodipine Besylate	Amlodipine Besylate	190	88
Atorvastatin Calcium	Atorvastatin Calcium	160	80
Gabapentin	Gabapentin	106	62
Losartan Potassium	Losartan Potassium	102	53
Lisinopril	Lisinopril	99	52
Metformin Hcl Er	Metformin Hcl	96	42
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	92	64
Levothyroxine Sodium	Levothyroxine Sodium	90	43
Januvia	Sitagliptin Phosphate	79	25
Trulicity	Dulaglutide	78	31
Metformin Hcl	Metformin Hcl	73	38
Telmisartan	Telmisartan	73	43
Fluticasone Propionate	Fluticasone Propionate	70	51
Pioglitazone Hcl	Pioglitazone Hcl	65	32
Donepezil Hcl	Donepezil Hcl	61	31
Glimepiride	Glimepiride	61	25
Alendronate Sodium	Alendronate Sodium	60	32
Celecoxib	Celecoxib	59	34
Chlorthalidone	Chlorthalidone	59	26
Sertraline Hcl	Sertraline Hcl	57	28
Furosemide	Furosemide	56	35
Jardiance	Empagliflozin	56	26
Metoprolol Succinate	Metoprolol Succinate	53	23
Spironolactone	Spironolactone	52	23
Memantine Hcl	Memantine Hcl	50	28
Pantoprazole Sodium	Pantoprazole Sodium	48	27
Prednisone	Prednisone	48	40
Trazodone Hcl	Trazodone Hcl	48	29
Hydrochlorothiazide	Hydrochlorothiazide	47	24
Meclizine Hcl	Meclizine Hcl	46	31
Meloxicam	Meloxicam	45	33
Tamsulosin Hcl	Tamsulosin Hcl	45	30
Tramadol Hcl	Tramadol Hcl	45	22
Glipizide Er	Glipizide	42	16
Carvedilol	Carvedilol	41	18
Ibuprofen	Ibuprofen	41	33
Alprazolam	Alprazolam	40	16
Famotidine	Famotidine	40	23
Simvastatin	Simvastatin	37	18
Mounjaro	Tirzepatide	35	16
Omeprazole	Omeprazole	35	17
Ezetimibe	Ezetimibe	34	19
Clonazepam	Clonazepam	33	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	16
Ozempic	Semaglutide	32	14
Folic Acid	Folic Acid	30	15
Glipizide	Glipizide	29	15
Montelukast Sodium	Montelukast Sodium	29	20
Tizanidine Hcl	Tizanidine Hcl	29	19
Valsartan	Valsartan	29	13
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	27	15
Finasteride	Finasteride	26	14
Terbinafine Hcl	Terbinafine Hcl	26	22
Azithromycin	Azithromycin	25	25
Ciclopirox	Ciclopirox	25	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	24	14
Duloxetine Hcl	Duloxetine Hcl	24	11
Clotrimazole	Clotrimazole	23	19
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	21
Escitalopram Oxalate	Escitalopram Oxalate	22	14
Hydroxyzine Hcl	Hydroxyzine Hcl	20	11
Allopurinol	Allopurinol	18	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	18	18
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	17	14
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	16
Triamcinolone Acetonide	Triamcinolone Acetonide	16	14
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Synjardy	Empagliflozin/Metformin Hcl	15	suppressed
Rybelsus	Semaglutide	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Eliquis	Apixaban	13	suppressed
Gemtesa	Vibegron	13	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Vascepa	Icosapent Ethyl	13	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Naproxen	Naproxen	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Bydureon Bcise	Exenatide Microspheres	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Sucralfate	Sucralfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error